Navigating Anthem (Elevance Health) Qulipta Prior Authorization

Understanding Qulipta and Anthem's Coverage Landscape

Qulipta (atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of migraine. As a high-volume prior authorization target, its coverage under Anthem-licensed plans, operating as part of Elevance Health, requires specific attention. Most specialty medications, including oral CGRP inhibitors, are managed through either the pharmacy or medical benefit, often involving Anthem's in-house PBM, CarelonRx (formerly IngenioRx).

Anthem Prior Authorization Submission Channels for Qulipta

Anthem utilizes distinct channels for prior authorization submissions, depending on whether Qulipta falls under the pharmacy or medical benefit. Identifying the correct pathway is crucial for efficient processing and avoiding unnecessary delays.

Key Submission Pathways:

• **Pharmacy Benefit:** For Qulipta covered under the pharmacy benefit, submissions typically route through CarelonRx's provider PA system. Electronic prior authorization (ePA) can be initiated via industry platforms like CoverMyMeds and Surescripts, which integrate with prescriber workflows.
• **Medical Benefit:** If Qulipta were to be covered under the medical benefit, medical PA submissions for Anthem-licensed plans are directed through Availity Essentials. Providers can also submit X12 278 transactions via clearinghouses for medical benefit prior authorizations.
• **Benefit Verification:** Always verify the specific benefit (pharmacy vs. medical) for Qulipta for each patient's Anthem plan, as this dictates the appropriate submission channel and policy application.

Accessing Anthem's Medical Policies and Clinical Criteria

Anthem operating companies publish their medical policy and clinical utilization management guidelines through provider sites accessible via Availity. These resources are essential for understanding the medical necessity criteria, step therapy requirements, and quantity limits applicable to medications like Qulipta. For pharmacy benefit drugs, CarelonRx manages and publishes its own specific clinical criteria.

Common Denial Reasons and Appeal Pathways for Qulipta with Anthem

Denials for specialty medications under Anthem often stem from issues such as medical necessity, failure to complete required step therapy, insufficient documentation, or non-formulary status. Denials are typically communicated via X12 277/835 transactions or status updates within Availity. Understanding these patterns is key to proactive management.

Navigating the Anthem Appeals Process:

• **Standard Medical PA Appeals:** Denials for medical benefit PAs follow the Anthem operating-company appeals process, detailed in the provider manual.
• **Pharmacy Benefit Appeals:** For Qulipta denials under the pharmacy benefit, the appeal pathway is managed through CarelonRx, with specific instructions provided in their communications.
• **Peer-to-Peer Review:** Peer-to-peer reviews are generally available across both medical and pharmacy benefit denials, offering an opportunity for a clinician discussion with an Anthem or CarelonRx medical director.
• **State-Specific Variations:** Be aware that appeal processes, particularly for Medicaid lines, can have material state-specific variations that must be followed.

Klivira's Role in Streamlining Anthem Qulipta PAs

Klivira automates the prior authorization workflow by integrating directly with your EMR and connecting to payer portals like Availity, and ePA platforms like CoverMyMeds and Surescripts. This automation helps healthcare organizations efficiently navigate the complexities of Anthem (Elevance Health) Qulipta prior authorization, reducing manual effort, accelerating decision times, and improving patient access to critical migraine therapies.